SSA
TRIL

Schonfeld Strategic Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-701,201
Closed -$6.8M – 2654
2021
Q2 		$6.8M Buy
701,201
+187,026
+36% +$1.76M 0.07% 385
2021
Q1 		$5.52M Sell
514,175
-57,500
-10% -$711K 0.07% 392
2020
Q4 		$8.41M Buy
571,675
+2,521
+0.4% +$36.4K 0.11% 267
2020
Q3 		$8.09M Buy
569,154
+169,654
+42% +$1.69M 0.15% 189
2020
Q2 		$3.23M Buy
399,500
+229,500
+135% +$1.42M 0.08% 297
2020
Q1 		$687K Buy
+170,000
New +$643K 0.04% 481
2017
Q1 		– Sell
-22,047
Closed -$125K – 785
2016
Q4 		$125K Buy
22,047
+2,047
+10% +$20.4K 0.02% 520
2016
Q3 		$296K Hold
20,000
– – 0.05% 318
2016
Q2 		$180K Buy
20,000
+9,159
+84% +$95.2K 0.04% 385
2016
Q1 		$100K Buy
+10,841
New +$91.4K 0.04% 286

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Schonfeld Strategic Advisors's TRIL Position: Q3 2021 in Review

Schonfeld Strategic Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 701,201 shares — an estimated $6.8M sold.

Schonfeld Strategic Advisors first reported a position in TRIL in Q1 2016 and held it in 10 quarters. The position peaked at $8.41M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Schonfeld Strategic Advisors reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 701,201 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $6.8M.
  • Schonfeld Strategic Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Trillium Therapeutics Inc. position peaked at $8.41M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.